Table 1

Characteristics of patients enrolled in placebo controlled, double blind, randomised controlled trials of the addition of tumour necrosis factor α blocking agents to methotrexate in patients with active rheumatoid arthritis

No of patients
First authorTherapeutic agentPlaceboActive treatmentAge (years)Female (%)Duration of RA (years)RF(+) (%)
NS, not stated; RF, rheumatoid factor.
*Combined treatment groups (3 mg/kg every 4 weeks, 3 mg/kg every 8 weeks, 10 mg/kg every 4 weeks, 10 mg/kg every 8 weeks).
†Treatment group that received 40 mg every other week.
Weinblatt 21Etanercept305950841386
Maini 19Infliximab88340*53788.581
Weinblatt 22Adalimumab6267†567812NS
Keystone 23Adalimumab200207†56751179